September 2001
Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p6
Trade Publication
No abstract available.


Related Articles

  • Slivers of light in biotech sector gloom. Boreham, Tim // Australasian Biotechnology;Sep2008, Vol. 18 Issue 3, p88 

    The article reports on the state of the biotechnology sector as of September 2009. The sector is demonstrating signs of recovery as it has outperformed the overall market in recent months. Established biotechnology companies are facing tough business conditions, including Biota which decided to...

  • Progen reports Phase II results for lung cancer.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p6 

    The article discusses the results of the Phase II trial of PI-88 in combination with docetaxel to patients with advanced non small cell lung cancer by Progen. The trial does not meet its endpoints of improving the progression-free rate compared to docetaxel alone. Chief executive officer Justus...

  • FDA fast-tracks Progen's anticancer drug.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p14 

    The article reports that the U.S. Food and Drug Administration has awarded fast track status to anticancer drug PI-88 from Progen Corp. The fast track designation was granted for the prevention of tumor recurrence in patients with hepatocellular carcinoma. It is designed to facilitate the...

  • AACR Roundup.  // BioWorld Today;4/21/2009, Vol. 20 Issue 75, p8 

    This article deals with the preclinical data presented by Progen Pharmaceuticals Ltd. on PG11144, which inhibits lysine specific demethylase 1 (LSD1). LSD1 refers to an enzyme that can silence tumor-suppressing genes. Results showed that PG11144 has an inhibitory effect on LSD1 which led to the...

  • Corrections.  // BioWorld Today;8/17/2007, Vol. 18 Issue 160, p2 

    Corrections to articles published in the August 16, 2007 issue of "BioWorld Today" are presented, which include the incorrect location of Progen Pharmaceuticals Ltd. and an article about a research antibody that targets amyloid-beta.

  • Progen-CSIRO Manufacturing Alliance.  // Chemical Week;8/24/2002-9/4/2002, Vol. 164 Issue 34, p33 

    Reports the agreement formed between Progen Industries and the Commonwealth Science and Industrial Research Organization of Australia in September 2002.

  • Ecarin Clotting Time is Sensitive to Heparinoids: Comparison of Two Different Techniques. Demir, Muzaffer; Iqbal, Omer; Untch, Brian; Hoppensteadt, Debra A.; Gaikwad, Bhavna S.; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Jan2001, Vol. 7 Issue 1, p38 

    Ecarin clotting time (ECT) is currently developed for the specific monitoring of antithrombin drugs, such as hirudin, argatroban, and hirulog. Aqueous reagent and dry chemistry technology have become available for ECT monitoring of antithrombin agents. Currently, many heparinoids and...

  • Progen Raising $61M For Phase III Cancer Trials.  // Bioworld Week;5/7/2007, Vol. 15 Issue 19, p5 

    The article reports that Progen Pharmaceuticals Ltd. entered agreements for financings that will raise about $61 million in Australia. Progen entered into definitive agreements with institutional and other investors to sell 6.9 million shares for $32.8 million, and the $4.5 per-share price...

  • Progen Pharmaceuticals new treatment on track for regulatory submission in Asia.  // Australasian Biotechnology;Mar2014, Vol. 24 Issue 1, p17 

    The article presents an update on the heparan sulfate mimetics being developed by Progen Pharmaceuticals Ltd. which target the tumor microenvironment and inhibit the enzyme heparanase and growth factors for use in oncology. It reports the trial on the efficacy and safety of heparanase inhibitor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics